NIOX vs. SN, EKF, CREO, IUG, NCYT, POLX, IHC, AVO, RUA, and SUN
Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include Smith & Nephew (SN), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), and Surgical Innovations Group (SUN). These companies are all part of the "medical devices" industry.
NIOX Group vs. Its Competitors
Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 35.2% of NIOX Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by insiders. Comparatively, 46.7% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Smith & Nephew has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Smith & Nephew presently has a consensus target price of GBX 7,840, indicating a potential upside of 606.94%. NIOX Group has a consensus target price of GBX 90, indicating a potential upside of 31.58%. Given Smith & Nephew's higher probable upside, equities analysts clearly believe Smith & Nephew is more favorable than NIOX Group.
In the previous week, Smith & Nephew and Smith & Nephew both had 2 articles in the media. Smith & Nephew's average media sentiment score of 0.67 beat NIOX Group's score of 0.34 indicating that Smith & Nephew is being referred to more favorably in the media.
NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.
NIOX Group has a net margin of 28.21% compared to Smith & Nephew's net margin of 5.41%. NIOX Group's return on equity of 13.29% beat Smith & Nephew's return on equity.
Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.6%. NIOX Group pays an annual dividend of GBX 1 per share and has a dividend yield of 1.5%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 4,126.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Smith & Nephew beats NIOX Group on 8 of the 15 factors compared between the two stocks.
Get NIOX Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NIOX Group Competitors List
Related Companies and Tools
This page (LON:NIOX) was last updated on 7/8/2025 by MarketBeat.com Staff